AZ advances creative China strategy as IL-6 antibody green-lighted

SHANGHAI – The Shanghai-based joint venture Wuxi-Medimmune has received the go-ahead to start clinical trials from Chinese regulators for anti-IL-6 antibody WBP216 (MEDI5117) as a therapeutic for autoimmune and inflammatory diseases, in particular rheumatoid arthritis (RA).